Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen TEZSPIRE (tezepelumab-ekko by Quarter
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide volume growth YoY (%) (%)
Amgen TEZSPIRE (tezepelumab-ekko: 32.0% in Q1 2026.
Latest, Q1 2026
32.0%
Period ended Mar 31, 2026
Change on a year earlier
–
History
3 quarters
Since Q3 2025
Sources
3
Documents cited below
Where the Q1 2026 figure comes from
“TEZSPIRE ® (tezepelumab-ekko) sales increased 20% year-over-year to $343 million in the first quarter, driven by 32% volume growth, partially offset by 8% from lower inventory levels.”
Source: Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | 32.0% | – | Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 51.0% | – | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 48.0% | – | Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗ |
Cite this data
StockData. (2026). Amgen TEZSPIRE (tezepelumab-ekko (%), quarterly Q3 2025–Q1 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-tezspire-vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.